Novo's kidney disease drug fails to improve blood pressure in phase 3, spurring $816M loss

Novo Nordisk’s late-stage kidney disease drug has failed to evoke significant change in systolic blood pressure, a loss that will cost the Danish drugmaker more than $800 million.